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Exploring the relationship of MBD1 protein binding CpG sites of 
methylated DNA 
By  
Shelby Scherer 
Under the mentorship of Dr. Amanda Stewart 
Abstract 
Methylated DNA binding (MBD) proteins control transcriptional regulation by binding 
methylated DNA at CpG islands to modulate transcriptional activation and silencing of 
specific genes such as tumor suppressors.  The goal is to explore the structure/function 
relationship between MBD proteins and methylated DNA recognition.  By synthesizing 
the methylated DNA binding region of the MBD1 protein, binding studies test the 
peptide’s affinity and specificity for methylated DNA.  Fluorescence, circular dichroism, 
and thermal denaturation techniques are utilized to determine the binding affinities and 
structures of peptides.  Studies of peptide mutations can monitor the effectiveness of 
methylated DNA binding compared to the original peptide.  The most structured peptide 
is expected to have the highest affinity and selectivity, leading to a peptide which can 
compete with the MBD1 protein for methylated DNA binding.  The binding region of the 
MBD1 protein is composed of a two-stranded β-sheet called a 𝛽-hairpin connected by a 
large loop region.  This was not observed in the initial peptide sequence.  Instead the CD 
indicated the structure to be random coil.  This was expected, the 𝛽-hairpin portion was 
synthesized without the full protein limiting favorable interactions to stabilize its 
structure.  However, a fluorescence binding study determined the peptide did bind DNA.  
Thermal denaturation studies were conducted showing the stability of the peptide.  
Mutants will be made to increase binding affinity and selectivity in the future.  This 
research could produce a series of peptides which can inhibit methylated DNA binding 
domains and reduce the silencing of tumor suppressor proteins, providing effective 
cancer therapeutics.   
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Introduction 
Methylated DNA binding proteins are a type of transcription factor which means 
they control transcriptional regulation.  Transcription factors typically contain repression 
and activation domains to turn genes on and off on the DNA strand1.  The methyl-CpG 
binding domain (MBD) proteins bind to the methylated DNA to regulate transcriptional 
silencing of specific genes such as tumor suppressors2.  The MDB1 protein typically 
binds at methylated CpG islands which are cytosine-rich regions.  The binding region 
contains a β-hairpin, a β-sheet containing two β-strands linked by a β-turn or loop region, 
which is known to exclusively bind the binding site in the methylated DNA.   
Synthesizing the peptide sequence where the MBD protein binds to the DNA will 
determine how well the protein binds without the full domain.  If it does not bind, some 
of the amino acids in the peptide will be substituted for those that are known to bind 
DNA and will maintain β-sheet structure and folding.  With the substitution of the amino 
acids, the β-hairpin structure will be monitored to ensure it is maintained. 
In a separate study, a different peptide was studied 
and it was determined that fluoro and hydroxyl 
substitutions on the hairpin result in lower stabilization 
than the corresponding amine –substitution and acetylated 
polyamines3.  This data has been taken into consideration 
for the amino acid sequences of the mutant MBD1 
peptides.  DNA binding molecules can disrupt CpG 
methylation, silencing tumor suppressing genes by 
hypermethylation of their associated CpG islands5,6.  
Figure 1.  MBD1 protein 
binding methyl-CpG 
islands in methylated 
DNA.  The 𝛽-sheet 
indicates the binding 
region of the protein.4 
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Hypermethylation of CpG islands has been associated with transcriptional silencing of 
various genes in cancer cells7.  One of the goals in binding a peptide sequence that has a 
higher affinity than the original would be to widen the minor groove of the DNA.  Doing 
this would disrupt the DNA methylation in the major groove8.  Binding the MDB1 
mutant and preventing the full MBD1 protein from binding, will hopefully enable tumor 
suppressor transcription and will prevent the methylated CpG islands from inhibiting 
transcription of genes like those that code for tumor suppressors. 
Normally, methylated CpG islands prevent the exon from acting as a template for 
receptor production9.  Therefore, high levels of CpG methylation has been known to lead 
to gene silencing.  This could be further explored to determine whether the silencing is 
caused by MBD proteins or if the protein only amplifies the methylated CpG 
transcriptional inhibition.   
The section of the MBD1 protein to 
be synthesized and analyzed is the binding 
region made up of 24 amino acids (Table 1 
and Figure 2).  The structure is expected to 
be a random coil instead of a β-sheet since 
the whole protein is not present to stabilize 
the region.  Mutations of the original 
peptide will also be synthesized and 
analyzed, and the most structured peptide is 
expected to have the highest binding affinity for 
the methyl-CpG islands. 
Figure 2. MBD1 binding region 
amino-acid chain synthesized 
and capped. 
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The goal is to understand the structure and function relationship between the 
peptide and methylated DNA binding.  Doing this can create a peptide that will 
specifically bind methylated DNA and in the future have a peptide that will competitively 
bind the DNA to regulate the transcription of genes such as tumor suppressors.  It is 
important to regulate this because silencing of tumor suppressor genes can be deadly and 
expression of too many tumor suppressors could be just as devastating.  The regulation of 
gene expression is very important, and successfully producing a peptide with the desired 
DNA binding properties is an important step in achieving this goal.  
Table 1. MBD1 Peptide Sequence and Mutant Peptide Sequence 
MBD1 Sequence Ac-QWKRRESFRKSGASFGRSDIYYQS-NH2 
Mutant Peptide Sequence Ac-GWKRRESWRKSGASFGRSDIYYQS-NH2 
MBD1 Short Hairpin Ac-GWKRRESWRSNGRSDIYYQS- NH2 
*MBD1 sequence is the original DNA binding sequence within the MBD1 protein10. 
 
Methods 
The MBD1 binding sequence (Table 1) was synthesized by solid phase peptide 
synthesis using PS3 Peptide Technologies Peptide Synthesizer.  All of the amino acids 
were coupled for 20 minutes and deprotected twice for 5 minutes.  The solvent used was 
DMF, the activator was HBTU and the deprotection solution was 20% piperidine.  The 
peptide was capped using acetic anhydride.  After synthesis the peptide was capped and 
removed from the reaction vessel with isopropanol and placed into a peptide flask.  The 
peptide flask was connected to a round bottom flask attached to nitrogen for bubbling.  
The solution was drained and more isopropanol was added and then rinsed by 
dichloromethane.  The sample was rinsed again and dried.  After the resin was dried, the 
peptide was cleaved from the resin using a cleavage cocktail of 95% TFA, 2.5% TIPS 
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and 2.5% water.  The solution was mixed and transferred into the peptide flask.  Nitrogen 
was added to allow a slow bubble which continued for two hours to cleave the resin from 
the peptide.  The solution was then drained and the resin was left in the peptide flask, 
thereby releasing the peptide into the round bottom flask.  About 2 ml of TFA was added 
to rinse the peptide flask to ensure all peptide was removed.  The peptide solution was 
evaporated to a very small volume before the peptide was precipitated with 20 mL of 
cold ether.  About 20 ml of DI water was also added.  The solution was poured into a 
separatory funnel.  The solution was mixed and then released into two samples.  The 
water layer, which contained the peptide, was collected and lyophilized to a powder.   
A solution that the peptide dissolved in had to be determined.  After determining a 
water-based solution to dissolve the peptide, a large portion of the peptide was added to 
about 5mL and filtered.  An HPLC was used to purify the peptide with a C-18 silica 
based reversed phase HPLC column.  A two solvent system was used, solvent A, 95% 
HPLC water, 5% Acetonitrile and 0.1% TFA, and solvent B, 95% acetonitrile, 5% HPLC 
water and 0.1% TFA.  The column was saturated with solvent A to equilibrate the 
column, and solvent B, was added to the column at the end of each peptide injection to 
wash the column fully.  About 0.2 mL of the solution was run on the HPLC, with a 0 to 
40% solvent B over 25 minutes, to determine the expected spectrum and the peptides 
elution time.  The peptide eluted around 16 minutes, which is about two-thirds of being 
full saturated.  Then, the volume was slowly increased and five different fractions were 
collected at the elution time.  After the peptide was purified it was placed on the 
lyophilizer. After lyophilizing the peptide fractions, a small amount of peptide from each 
fraction was dissolved in 50 µL of water.  Then 1µL was placed on a well of the MALDI 
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TOF plate and when it was almost dry 1µL of matrix was added on top of it.  A Bruker 
Microflex MALDI-ToF mass spectrometer, to determine the mass of each of the fractions 
collected from HPLC was used to determine the mass of the peptide.  Then 583µL 6M 
GuHCl buffer, 100 µL peptide and 17µL of 10 mM Na2HPO4 buffer was added to a 
cuvette and the absorbance was measured using a UV spectrometer at 280nm.  The 
absorbance was used to determine the concentration of the peptide.  Then the peptide was 
diluted to about 7 mM using 10mM Na2HPO4 buffer and run on the CD instrument.  The 
data was analyzed to determine its secondary structure.   
The concentration of the single strand DNA sequences were determined to be 
590µM and 485µM.  Amounts of DNA were added to produce a 242 µM double helix 
DNA.  The DNA was then annealed and the absorbance was taken at 260 nm and then 
used to determine the concentration.  A fluorescence binding study was performed 
maintaining 5µM MBD1 peptide concentration and increasing the methylated DNA 
concentration (Table 2).  Using these solutions, samples of peptide and DNA were micro-
pipetted into a 700 µL cuvette using low retention pipette tips.  The instrument used was 
a fluorescence spectrometer.  Each sample was run twice and then averaged.   
A thermal denaturation analysis was conducted using a 10µM MBD1 peptide in 
10mM Na2HPO4 solution.  Then the solution was analyzed in a thermal denaturation 
experiment via circular dichroism.  This was conducted at 222 nm with a temperature 
range of 5-95°C.  The system would stand at each degree for 60 seconds and then rest for 
60 seconds for a total of 90 cycles.   
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A CD analysis was then performed using three samples.  A10µM MBD1 peptide 
in 10 mM Na2HPO4, 10 µM MBD1 peptide and 10 µM methylated DNA, and the third 
contained only 10µM methylated DNA.  The system was set to run from 260 to 190 nm.   
Results  
Synthesis and Purification of MBD1 Binding Sequence 
The MBD1 peptide was synthesized, cleaved and purified twice because the first 
synthesis did not couple properly.  After cleaving and lyophilizing the peptide, it was 
dissolved in a solvent.  It was not soluble in any of the solutions containing TFA.  
However, it dissolved best in about 5mL of 90% DI water and 10% acetonitrile.  All 
other solutions would result in it crashing out or not dissolving.  It was sonicated for 
many minutes throughout the peptide additions.  Only small samples of peptide were 
added over time to ensure it was properly dissolving.  After it was dissolved, the peptide 
was filtered to prevent dust and other particles from clogging the needles and HPLC.  
Before each purification run, A Wash was run for 10 minutes to re-equilibrate the column 
with polar solvent.  After filtering the peptide, a small amount (about 200µL) was 
injected into the HPLC.  The system ran for the full 25 minutes to determine when the 
peptide eluted.  After that, larger increments of the peptide solution was added and 
collected in five separate fractions.  This was to ensure that the peptide was properly 
purified because; each peak could contain many different peptides but the major peak 
was expected to have the desired peptide.  Therefore, five fractions were collected before, 
during and after the major peak to separate the MBD1 peptide from sample (Figure 3).  
Many sessions of fractions were collected to purify the entire peptide.  After each 
purification, nonpolar solvent B was run in order to remove any peptide or other 
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substance that stuck on the column.  The peptide fractions were then lyophilized to be 
prepared for mass spectrometry. 
 
Figure 3. MBD1 peptide HPLC peak from 800 µL of peptide dissolved in water 
Peptide Characterization 
After preparing the mass spectrometer samples, the laser strikes the sample, 
ionizing it and then the detector determines the mass of the products in the sample.  This 
was done for each of the samples.  The expected mass of the synthesized peptide 
sequence was 2910.  The best peak was 2915 from fraction 4 (Figure 4).  Fraction 3 was 
expected to have the most pure peptide since it was from the top of the peak, however 
this was not the case.  Instead the fraction that had the peak below was used for the 
remainder of the experiment.  
 
 
 
9 
 
 
 
Figure 4. MALDI-ToF data of purified MBD1 peptide.  Peak expected at 2910. 
 After determining that the correct peptide was present in fraction 4, the peptide 
was dissolved in 10mM Na2HPO4 buffer, pH 7, to be analyzed using UV-Vis at 
wavelength of 280nm.  The absorbance was used to determine the concentration of the 
peptide which was 31.2 µM.  A peptide sample of the 31.2 µM peptide solution was 
analyzed via circular dichroism (CD) to determine the structure.  The peptide 
concentration was diluted from 31µM to 7.5µM using the 10mM Na2HPO4.  The CD 
indicated the structure to be a random coil based on its minimum peak at 195nm, which is 
the characteristic of a random coil peptide structure (Figure 5). 
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Figure 5. CD wavelength data for 7.5µM MBD1 peptide analyzed from 260-190nm at 
25°C.  
Binding Studies  
After determining the structure of the peptide, the single stranded methylated 
DNA concentrations were determined and annealed to produce 242µM double stranded 
methylated DNA. To prepare for the 
binding study, a constant 
concentration of 5µM peptide was 
added to each low retention tube and the 
methylated DNA was added by increasing the concentration in each tube (Table 2).   
Table 2.  Concentrations of Peptide, Buffer, and DNA for Fluorescence binding study 
Sample Peptide (µL) Buffer (µL) DNA (µL) [DNA] mM 
1 120 680 0 0 
2 120 673 7 2 
3 120 663 17 5 
4 120 647 33 10 
5 120 630 50 15 
6 120 614 66 20 
7 120 597 83 25 
8 120 581 99 30 
9 120 548 132 40 
10 120 515 165 50 
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Each sample was analyzed twice, using the fluorimeter to detect tryptophan fluorescence 
emission scan.  The two runs were averaged to produce a binding curve.  The decrease of 
the fluorescence intensity curve shows tryptophan quenching and indicates that the 
peptide binds the DNA (Figure 7).   
  
Thermal Denaturation and Circular Dichroism Analysis 
The thermal denaturation heated the MBD1 peptide from 5°C to 95°C.  The 
sample would heat for one minute and then equilibrate to that temperature for one minute 
for a series of 90 cycles (Figure 7).  For the thermal denaturation study the peptide begins 
at its “fully folded” structure at 5°C and ends at 95°C where it is presumed to be fully 
unfolded.  The full protein would have an “S shaped” denaturation curve.  However, this 
peptide does not have a regularly structured beta sheet therefore, the melting temperature 
is expected to be lower than the full protein or a peptide that is more structurally stable.  
However, this is mainly a linear negative slope (Figure 8).  The denaturation also 
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provides the melting point of the peptide.  The melting temperature for this MBD1 
peptide was determined to be 49°C, which is the temperature in which the peptide is 50% 
folded.   
 
Figure 8.  MDB1 thermal denaturation from 5°C to 95°C using Circular Dichroism at a 
constant wavelength of 222nm. 
The CD analysis samples were then prepared.  The 10µM MBD1 peptide in 
10mM Na2HPO4, 10µM MBD1 peptide and 10µM methylated DNA, and the 10µM 
methylated DNA samples were analyzed using the CD to determine their structures 
(Figure 9).  The peptide once again maintained the random coil structure.  The reason for 
the second run of the peptide was to be able to compare the structures with the same 
concentration.  In figure 9, the structure of the peptide, DNA, peptide and DNA (mixed) 
and the peptide and DNA (additive) can be compared to show the binding of the peptide 
and DNA.  The peptide (grey) is expected to have a random coil signal which it does and 
the DNA (blue) is expected to have a double helical structure.  The peptide and DNA 
mixed (orange) line and the peptide and DNA (additive) lines are not the same which 
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indicate that binding is occurring.  The mixed value was recorded using the CD to 
visualize the structure, whereas the additive value was determined by averaging the 
peptide and DNA signals.  The reason for this was to determine if there was actual 
binding or if the signal was a simple average of the individual signals. 
 
Figure 9.  The circular dichroism structure study of MBD1 peptide, MBD1 peptide with 
DNA and DNA (mix) and (additive). 
Discussion and Conclusion 
The peptide was synthesized twice because the first synthesis did not result in the 
desired peptide mass on MALDI-ToF.  That is the reason for the extended coupling of the 
central amino acids in the sequence.  Based on the mass of the first synthesized peptide, it 
is thought that the alanine did not couple to the peptide properly, resulting in the incorrect 
peptide mass.  The second synthesis resulted in a mass very close to the expected 2910.  
The peptide did not initially dissolve in many of the solutions which is under inspection 
by other individuals.  Researchers in the Stewart lab have determined that there is a high 
concentration of sodium ion and other ions in the local water samples.  It is thought that 
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sodium binds to tryptophan and other amino acids in the peptide sequence, disrupting the 
peptide’s structure and causing the peptide to precipitate from solution.  The sodium 
binding would result in disruption in the structure of the peptide and also the binding of 
the peptide with the methylated DNA.   
After the proper mass was determined, the CD spectrometer was used to 
determine the secondary structure.  The shape of the sequence when present in the full 
protein consists of one β-sheet connected by a loop region, however, without the entire 
peptide the structure was unknown.  After running the CD, the structure was determined 
to be a random coil (Figure 4).  This was expected since the full peptide was not present 
to help maintain the full β-sheet structure.  For the mutants to be synthesized in the 
future, a couple of the amino acids will be exchanged, intended to restructure the peptide 
into the β-sheet-loop region- β-sheet structure of the MBD1 binding site.   In the first 
mutant a glutamine will be substituted for a glycine at the N terminus and a 
phenylalanine will be replaced with a tryptophan in order to create a mutant peptide.   
Glycine is the smallest amino acid and helps with tight loops in the beta sheets and 
tryptophans are regularly found in β-sheets because their indole ring is larger.  The indole 
ring provides more potential pi-pi interactions to allow stacking with the DNA bases.  
They also have a fluorescence quality which is helpful for binding studies.  In the MBD1 
original peptide sequence, only one tryptophan is present and it is present in the β-sheet 
region instead of the loop region.  The loop region is expected to bind with the DNA with 
base stacking whereas the β-sheet region may only have weak electrostatic interactions 
with the methylated DNA. 
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The fluorescence binding study, indicated binding between the MBD1 peptide 
and the methylated DNA.  Tryptophan is the amino acid that possesses fluorescence 
properties and can be monitored for changes in fluorescence based on DNA binding.  
When bound to methylated DNA, the emission is quenched and therefore decreases its 
fluorescence intensity.  As the concentration of the DNA is increased, the fluorescence 
emission decreases which indicates binding.  This data can be graphed to produce a 
binding curve.  Higher concentrations of DNA were used in order to saturate binding 
sites to determine an accurate dissociation constant.  With the mutant peptides, a 
decreased fluorescence intensity is expected and will indicate improved binding.     
The thermal denaturation study provided the information need to determine the 
melting temperature of the MDB1 peptide to be 49°C.  This data will be compared to 
future synthesized peptide sequences to determine the peptides stability and denaturation 
characteristics.  The peptide having the highest binding affinity for methylated DNA is 
expected to have the most structure, highest melting temperature, and highest specificity, 
but this must be confirmed by binding and structural studies.  The CD study comparing 
10µM samples of peptide, DNA, peptide and DNA (mixed), and peptide and DNA 
(additive) indicate again that binding is present.  Unlike the fluorescence binding study, 
the peptide and DNA concentration are the same in the sample.  The data shows the 
structure of the peptide and DNA together.  In order to be compared, the intensities of the 
peptide and DNA structures were averaged and then plotted.  The mixed and additive 
graphs are not the same.  They do not provide a signal for a specific structure but since 
there is a difference between the additive and the mixed that is an indication of binding 
rather than a simple average of the two signals.  The structural difference will also be 
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compared to future peptides in order to determine if the mutant bind more specifically 
than the original MBD1 binding sequence.  The future peptides will be analyzed with 
binding and structural studies to determine a peptide sequence that can achieve high 
affinity and sequence selectivity.  These will be used to determine a structure-function 
relationship for methylated DNA binding by peptides and proteins. 
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